Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2004

View Archived Issues

Sphingosine kinase type 2 involved in phosphorylation of immunosuppressant FTY-720

Significant improvements reported with atorvastatin in NASH

FluMist reported to protect healthy children against natural influenza infection

Nolomirole attenuates heart failure

In vivo attenuation of nonseptic shock by superoxide dismutase mimetic M-40401

DA-8159 effective for inducing erection in rabbit models of spinal cord injury

Lorus Therapeutics makes solid progress in advanced clinical programs during 1H of fiscal 2004

Drug candidates from lead programs at Rigel enter clinic in 2003

Pharmacyclics broadens clinical development of Xcytrin during Q2

Gilead announces year-end 2003 product pipeline highlights

Array BioPharma signs two important agreements during Q2 FY2004

CEP-1347 reported well tolerated in Parkinson's disease patients

Preliminary analysis of phase I Oxycyte study

Estrogel receives FDA approval

Melanotan implant study produces encouraging results

Two series of antibacterial oxazolidinones recently designed at Pharmacia

NitroMed claims new NO-releasing COX-2 inhibitors

Novel antitumor agents in early development at Zentaris

New antiobesity MCH antagonists developed by Schering-Plough researchers

Novel beta-secretase inhibitors emerge from Actelion R&D

Merck & Isis collaboration yields novel HCV NS5B inhibitors

Novo Nordisk claims novel glucagon receptor inhibitors and their use

New prodrugs of thrombin inhibitors covered by LG Life Sciences patent

E-2000 Japanese NDA withdrawn

PRX-00023 enters clinical testing

Ultrafine completes manufacture to GMP of ATI-2042

Approval for generic formulations of Lotensin

First phase of Dermicol testing completed

Tularik advances T-71 into phase I

Valeant to acquire Amarin U.S. operations

New phase II study for MT-201 in prostate cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026